The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy

Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60...

Full description

Saved in:
Bibliographic Details
Published inCancer medicine (Malden, MA) Vol. 9; no. 1; pp. 43 - 51
Main Authors Park, Hyunkyung, Bang, Ju‐Hee, Nam, Ah‐Rong, Park, Ji Eun, Jin, Mei Hua, Bang, Yung‐Jue, Oh, Do‐Youn
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.01.2020
John Wiley and Sons Inc
Wiley
Subjects
Antigens
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
biomarker
Biomarkers
Biomarkers, Tumor - blood
Blood
Blood platelets
Chemotherapy
Clinical Cancer Research
Diagnosis
Disease Progression
Female
Fluorouracil - therapeutic use
Growth factors
Humans
Irinotecan - therapeutic use
Kaplan-Meier Estimate
Laboratories
Leucovorin - therapeutic use
Lymphocytes
Male
Medical prognosis
Metastasis
Middle Aged
Neutrophils
Original Research
Oxaliplatin - therapeutic use
Palliative Care - methods
Pancreatic cancer
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - mortality
Pathogenesis
Patients
Prognosis
Progression-Free Survival
Prospective Studies
Survival
Transforming Growth Factor beta - blood
Transforming growth factor-b
transforming growth factor‐beta
transforming growth factor-beta
pancreatic cancer
biomarker
chemotherapy
prognosis
Online AccessGet full text

Cover

Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay. Results The patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF‐β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF‐β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF‐β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). Conclusions Pretreatment sTGF‐β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF‐β during chemotherapy have prognostic value. Pre‐treatment sTGF‐β levels serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. The dynamics of sTGF‐β during chemotherapy have prognostic value.
AbstractList Pre‐treatment sTGF‐β levels serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. The dynamics of sTGF‐β during chemotherapy have prognostic value.
Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay. Results The patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF‐β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF‐β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF‐β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). Conclusions Pretreatment sTGF‐β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF‐β during chemotherapy have prognostic value. Pre‐treatment sTGF‐β levels serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. The dynamics of sTGF‐β during chemotherapy have prognostic value.
Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay. Results The patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF‐β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF‐β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF‐β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). Conclusions Pretreatment sTGF‐β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF‐β during chemotherapy have prognostic value.
Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. Methods We prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay. Results The patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF‐β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P =  .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P =  .034). At the time of disease progression, sTGF‐β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF‐β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P =  .049). Conclusions Pretreatment sTGF‐β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF‐β during chemotherapy have prognostic value.
ObjectivesTransforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients.MethodsWe prospectively enrolled 60 patients treated with FOLFIRINOX as the first‐line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF‐β using an enzyme‐linked immunosorbent assay.ResultsThe patients’ median overall survival (OS) and progression‐free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5‐12.1) and 6.5 (95% CI, 4.9‐8.1) months, respectively. Patients with low sTGF‐β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF‐β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF‐β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF‐β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049).ConclusionsPretreatment sTGF‐β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF‐β during chemotherapy have prognostic value.
Transforming growth factor-beta (TGF-β) is a multifunctional regulatory factor. Here we measured serum soluble TGF-β (sTGF-β) levels and evaluated its dynamics and prognostic capabilities during chemotherapy in unresectable pancreatic cancer patients. We prospectively enrolled 60 patients treated with FOLFIRINOX as the first-line palliative chemotherapy. We collected blood samples at the time of diagnosis, first response assessment, and disease progression and measured serum sTGF-β using an enzyme-linked immunosorbent assay. The patients' median overall survival (OS) and progression-free survival (PFS) were 10.3 (95% confidence interval [CI], 8.5-12.1) and 6.5 (95% CI, 4.9-8.1) months, respectively. Patients with low sTGF-β at diagnosis (<31.2 ng/mL) had better OS and PFS than patients with high sTGF-β, respectively, (OS, 13.7 vs 9.2 months; hazard ratio [HR], 2.602; P = .004; PFS, 9.0 vs 5.8 months; HR, 2.010; P = .034). At the time of disease progression, sTGF-β was increased compared with that of diagnosis (mean, 26.4 vs 23.9 ng/mL). In particular, sTGF-β was significantly increased at disease progression in patients with a partial response (mean, 25.7 vs 31.0 ng/mL; P = .049). Pretreatment sTGF-β levels can serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. Likewise, the dynamics of sTGF-β during chemotherapy have prognostic value.
Author Park, Hyunkyung
Park, Ji Eun
Oh, Do‐Youn
Nam, Ah‐Rong
Bang, Yung‐Jue
Jin, Mei Hua
Bang, Ju‐Hee
AuthorAffiliation 2 Cancer Research Institute Seoul National University College of Medicine Seoul Korea
1 Department of Internal Medicine Seoul National University College of Medicine Seoul Korea
AuthorAffiliation_xml – name: 1 Department of Internal Medicine Seoul National University College of Medicine Seoul Korea
– name: 2 Cancer Research Institute Seoul National University College of Medicine Seoul Korea
Author_xml – sequence: 1
  givenname: Hyunkyung
  orcidid: 0000-0002-5646-8054
  surname: Park
  fullname: Park, Hyunkyung
  organization: Seoul National University College of Medicine
– sequence: 2
  givenname: Ju‐Hee
  surname: Bang
  fullname: Bang, Ju‐Hee
  organization: Seoul National University College of Medicine
– sequence: 3
  givenname: Ah‐Rong
  surname: Nam
  fullname: Nam, Ah‐Rong
  organization: Seoul National University College of Medicine
– sequence: 4
  givenname: Ji Eun
  surname: Park
  fullname: Park, Ji Eun
  organization: Seoul National University College of Medicine
– sequence: 5
  givenname: Mei Hua
  surname: Jin
  fullname: Jin, Mei Hua
  organization: Seoul National University College of Medicine
– sequence: 6
  givenname: Yung‐Jue
  surname: Bang
  fullname: Bang, Yung‐Jue
  organization: Seoul National University College of Medicine
– sequence: 7
  givenname: Do‐Youn
  surname: Oh
  fullname: Oh, Do‐Youn
  email: ohdoyoun@snu.ac.kr
  organization: Seoul National University College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31701645$$D View this record in MEDLINE/PubMed
BookMark eNp1kctu3CAUhlGVqkmmWfQFKqSuupgEDPiyqRSNmouUqpvpGh3w8dgjG1zwJJpdH6HP2CcpzqRRsigbDvDp48B_So6cd0jIB87OOWPZhYVBnmd5UbwhJxmTalnkQh69qI_JWYxblkbBEsffkWPBC8ZzqU7I_bpFOga_cT5OnaXB90h9Q6PvdyaV6-urP79-G5yAgqtpN0Va7x0MnY20c3TnAka0E8zsCM4GhFljU4mBTvMSa_rQTS21LQ5-ajHAuH9P3jbQRzx7mhfkx9XX9epmeff9-nZ1ebe0ilXFUpqqLKVUtcyzXPHCyqrBghsuoDKiBKwrw5golTLGlgKFVGDSV0AmABkUYkFuD97aw1aPoRsg7LWHTj9u-LDREFLDPWqOVXJinamslFjYShprS5ZXTQOc8zK5vhxc484MWFt0U4D-lfT1ietavfH3Oq-k4FIlwacnQfA_dxgnvfW74NL7dSaEUIzzNC3I5wNlg48xYPN8A2d6TlzPies58cR-fNnSM_kv3wRcHICHrsf9_016dflNPir_AjyKuO8
CitedBy_id crossref_primary_10_3390_biom12091315
crossref_primary_10_3389_fonc_2020_597672
crossref_primary_10_3390_cancers12123871
crossref_primary_10_1186_s12957_020_01981_x
crossref_primary_10_1016_j_hpb_2021_05_001
crossref_primary_10_1053_j_gastro_2021_04_064
crossref_primary_10_2217_imt_2022_0046
crossref_primary_10_1186_s13046_021_01946_2
crossref_primary_10_3390_ijms21103534
crossref_primary_10_1007_s10555_021_09981_3
crossref_primary_10_3390_cancers14040973
crossref_primary_10_3390_life12070960
crossref_primary_10_3390_ijms242015332
Cites_doi 10.18632/oncotarget.5682
10.1634/theoncologist.2016-0178
10.1056/NEJMoa1304369
10.18632/oncotarget.3069
10.1158/1078-0432.CCR-1096-03
10.1200/JCO.2005.05.3934
10.1371/journal.pone.0085942
10.4143/crt.2018.311
10.1038/onc.2013.29
10.1016/j.ejca.2008.10.026
10.1136/gut.2004.047191
10.1038/bjc.2013.332
10.1016/S0140-6736(04)15841-8
10.1016/j.bbrc.2017.05.034
10.1002/bjs.4484
10.1097/00000658-199912000-00006
10.1186/1476-4598-12-66
10.18632/oncotarget.8847
10.1038/sj.bjc.6604745
10.1038/cr.2008.316
10.1002/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5
10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X
10.1016/0016-5085(93)91084-U
10.1016/j.pan.2014.12.004
10.1007/s00432-016-2184-6
10.1158/1078-0432.CCR-07-1157
10.1038/nrc1208
10.18632/oncotarget.10069
10.3109/07357907.2014.1001894
10.1016/j.cca.2006.02.027
10.1097/PPO.0000000000000045
10.1023/A:1018814416903
10.1093/neuonc/nox097
10.1056/NEJMoa1011923
10.1016/j.ccr.2005.10.012
10.1159/000108959
10.1158/1541-7786.MCR-12-0511
ContentType Journal Article
Copyright 2019 The Authors. published by John Wiley & Sons Ltd.
2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2019 The Authors. published by John Wiley & Sons Ltd.
– notice: 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
– notice: 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
3V.
7X7
7XB
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M7P
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
5PM
DOA
DOI 10.1002/cam4.2677
DatabaseName Wiley-Blackwell Open Access Collection
Wiley-Blackwell Open Access Backfiles
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
ProQuest Central (Corporate)
Health & Medical Collection (Proquest)
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
AUTh Library subscriptions: ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni Edition)
Biological Science Database
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest Central (Alumni)
DatabaseTitleList


CrossRef
Publicly Available Content Database
MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley-Blackwell Open Access Collection
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: AUTh Library subscriptions: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate PARK et al
EISSN 2045-7634
EndPage 51
ExternalDocumentID oai_doaj_org_article_1e99b3ed25284e7c94bcc8069ffa1118
10_1002_cam4_2677
31701645
CAM42677
Genre article
Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GrantInformation_xml – fundername: SNU Invitation Program for Distinguished Scholar
– fundername: Astrazeneca‐KHIDI
  funderid: 06‐2016‐2920
– fundername: Astrazeneca‐KHIDI
  grantid: 06‐2016‐2920
GroupedDBID 0R~
1OC
24P
31~
53G
5VS
7X7
8-0
8-1
8FE
8FH
8FI
8FJ
AAHHS
AAZKR
ABDBF
ABUWG
ACCFJ
ACXQS
ADBBV
ADKYN
ADRAZ
ADZMN
ADZOD
AEEZP
AENEX
AEQDE
AFKRA
AIWBW
AJBDE
ALAGY
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AOIJS
AVUZU
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
D-8
D-9
DIK
EBS
EJD
FYUFA
GODZA
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
HZ~
IAO
IHR
KQ8
LK8
M48
M7P
M~E
O9-
OK1
OVD
PIMPY
PQQKQ
PROAC
RPM
TEORI
TUS
UKHRP
WIN
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
3V.
7XB
8FK
AZQEC
DWQXO
GNUQQ
K9.
PQEST
PQUKI
PRINS
5PM
ID FETCH-LOGICAL-c5097-4b988445d4626517c49fe71b13a9b38aed9b003855bbc83e345ab677a23ae0a73
IEDL.DBID RPM
ISSN 2045-7634
IngestDate Fri Oct 04 13:13:52 EDT 2024
Tue Sep 17 21:18:41 EDT 2024
Thu Oct 10 20:12:04 EDT 2024
Thu Sep 26 19:09:34 EDT 2024
Sat Sep 28 08:32:44 EDT 2024
Sat Aug 24 01:08:28 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords transforming growth factor-beta
pancreatic cancer
biomarker
chemotherapy
prognosis
Language English
License Attribution
2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5097-4b988445d4626517c49fe71b13a9b38aed9b003855bbc83e345ab677a23ae0a73
ORCID 0000-0002-5646-8054
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943145/
PMID 31701645
PQID 2333501133
PQPubID 2032540
PageCount 9
ParticipantIDs doaj_primary_oai_doaj_org_article_1e99b3ed25284e7c94bcc8069ffa1118
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6943145
proquest_journals_2333501133
crossref_primary_10_1002_cam4_2677
pubmed_primary_31701645
wiley_primary_10_1002_cam4_2677_CAM42677
PublicationCentury 2000
PublicationDate January 2020
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – month: 01
  year: 2020
  text: January 2020
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bognor Regis
– name: Hoboken
PublicationTitle Cancer medicine (Malden, MA)
PublicationTitleAlternate Cancer Med
PublicationYear 2020
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2009; 45
2001; 92
2004; 363
2015; 15
2015; 6
2019; 51
2013; 109
1997; 42
2013; 369
2017; 22
2015; 33
2006; 371
2008; 99
1999; 85
2004; 91
1993; 105
2007; 13
2016; 142
2014; 20
1992; 52
2004; 10
2016; 7
2012; 3
2013; 11
2013; 32
2006; 24
2013; 12
2005; 8
1999; 230
2003; 3
2005; 54
2007; 7
2017; 19
1998; 7
2014; 9
2009; 19
2017; 488
2011; 364
e_1_2_9_30_1
e_1_2_9_31_1
e_1_2_9_11_1
e_1_2_9_34_1
e_1_2_9_10_1
e_1_2_9_35_1
e_1_2_9_13_1
e_1_2_9_32_1
Malik NK (e_1_2_9_4_1) 2012; 3
e_1_2_9_12_1
e_1_2_9_33_1
e_1_2_9_15_1
e_1_2_9_38_1
e_1_2_9_14_1
e_1_2_9_39_1
e_1_2_9_17_1
e_1_2_9_36_1
e_1_2_9_16_1
e_1_2_9_37_1
e_1_2_9_19_1
e_1_2_9_18_1
Picon A (e_1_2_9_23_1) 1998; 7
e_1_2_9_41_1
e_1_2_9_20_1
e_1_2_9_40_1
e_1_2_9_21_1
e_1_2_9_24_1
e_1_2_9_8_1
e_1_2_9_7_1
e_1_2_9_6_1
e_1_2_9_5_1
e_1_2_9_3_1
e_1_2_9_2_1
Gorsch SM (e_1_2_9_22_1) 1992; 52
e_1_2_9_9_1
e_1_2_9_26_1
e_1_2_9_25_1
e_1_2_9_28_1
e_1_2_9_27_1
e_1_2_9_29_1
References_xml – volume: 52
  start-page: 6949
  issue: 24
  year: 1992
  end-page: 6952
  article-title: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer
  publication-title: Can Res
– volume: 363
  start-page: 1049
  issue: 9414
  year: 2004
  end-page: 1057
  article-title: Pancreatic cancer
  publication-title: Lancet
– volume: 7
  start-page: 423
  issue: 5–6
  year: 2007
  end-page: 435
  article-title: Basics of TGF‐beta and pancreatic cancer
  publication-title: Pancreatology
– volume: 19
  start-page: 89
  issue: 1
  year: 2009
  end-page: 102
  article-title: Roles of TGFbeta in metastasis
  publication-title: Cell Res
– volume: 32
  start-page: 5253
  issue: 45
  year: 2013
  end-page: 5260
  article-title: Evolution and dynamics of pancreatic cancer progression
  publication-title: Oncogene
– volume: 22
  start-page: 1049
  issue: 9
  year: 2017
  end-page: 1055
  article-title: Cell‐free DNA in metastatic colorectal cancer: a systematic review and meta‐analysis
  publication-title: Oncologist
– volume: 142
  start-page: 1727
  issue: 8
  year: 2016
  end-page: 1738
  article-title: Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first‐line treatment of metastatic or recurrent gastric cancer
  publication-title: J Cancer Res Clin Oncol
– volume: 85
  start-page: 554
  issue: 3
  year: 1999
  end-page: 561
  article-title: Elevated serum levels of transforming growth factor‐beta1 in patients with colorectal carcinoma: its association with tumor progression and its significant decrease after curative surgical resection
  publication-title: Cancer
– volume: 42
  start-page: 2054
  issue: 10
  year: 1997
  end-page: 2063
  article-title: Presence of two signaling TGF‐beta receptors in human pancreatic cancer correlates with advanced tumor stage
  publication-title: Dig Dis Sci
– volume: 9
  issue: 1
  year: 2014
  article-title: Biomarkers of TGF‐beta signaling pathway and prognosis of pancreatic cancer
  publication-title: PLoS ONE
– volume: 99
  start-page: 1695
  issue: 10
  year: 2008
  end-page: 1703
  article-title: Blockade of SDF‐1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway
  publication-title: Br J Cancer
– volume: 7
  start-page: 44583
  issue: 28
  year: 2016
  end-page: 44595
  article-title: Circulating cell‐free DNA as a prognostic and predictive biomarker in non‐small cell lung cancer
  publication-title: Oncotarget
– volume: 488
  start-page: 196
  issue: 1
  year: 2017
  end-page: 203
  article-title: CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF‐β pathway in human non‐small cell lung cancer
  publication-title: Biochem Biophys Res Comm
– volume: 7
  start-page: 33035
  issue: 22
  year: 2016
  end-page: 33045
  article-title: High post‐treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients
  publication-title: Oncotarget
– volume: 51
  start-page: 832
  issue: 2
  year: 2019
  end-page: 840
  article-title: Dynamics of soluble programmed death‐ligand 1 (sPDL1) during chemotherapy and its prognostic implications in cancer patients: biomarker development in immuno‐oncology
  publication-title: Cancer Res Treat
– volume: 371
  start-page: 191
  issue: 1–2
  year: 2006
  end-page: 193
  article-title: Elevated plasma TGF‐beta1 levels correlate with decreased survival of metastatic breast cancer patients
  publication-title: Clin Chim Acta
– volume: 19
  start-page: 1618
  issue: 12
  year: 2017
  end-page: 1627
  article-title: Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma
  publication-title: Neuro‐oncology
– volume: 91
  start-page: 586
  issue: 5
  year: 2004
  end-page: 594
  article-title: Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma
  publication-title: Br J Surg
– volume: 12
  start-page: 66
  year: 2013
  article-title: Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand‐independent manner
  publication-title: Mol Cancer
– volume: 10
  start-page: 2738
  issue: 8
  year: 2004
  end-page: 2741
  article-title: Plasma level of transforming growth factor beta1 measured from the azygos vein predicts prognosis in patients with esophageal cancer
  publication-title: Clin Cancer Res
– volume: 24
  start-page: 2897
  issue: 18
  year: 2006
  end-page: 2902
  article-title: Perioperative CA19‐9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma
  publication-title: J Clin Oncol
– volume: 3
  start-page: 807
  issue: 11
  year: 2003
  end-page: 821
  article-title: Cytostatic and apoptotic actions of TGF‐beta in homeostasis and cancer
  publication-title: Nat Rev Cancer
– volume: 3
  start-page: 326
  issue: 4
  year: 2012
  end-page: 334
  article-title: Treatment of locally advanced unresectable pancreatic cancer: a 10‐year experience
  publication-title: J Gastrointest Oncol
– volume: 364
  start-page: 1817
  issue: 19
  year: 2011
  end-page: 1825
  article-title: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer
  publication-title: N Engl J Med
– volume: 6
  start-page: 4717
  issue: 7
  year: 2015
  end-page: 4732
  article-title: Stromal‐derived factor‐1alpha/CXCL12‐CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer
  publication-title: Oncotarget
– volume: 369
  start-page: 1691
  issue: 18
  year: 2013
  end-page: 1703
  article-title: Increased survival in pancreatic cancer with nab‐paclitaxel plus gemcitabine
  publication-title: N Engl J Med
– volume: 105
  start-page: 1846
  issue: 6
  year: 1993
  end-page: 1856
  article-title: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
  publication-title: Gastroenterology
– volume: 11
  start-page: 768
  issue: 7
  year: 2013
  end-page: 779
  article-title: Stem cell marker nestin is critical for TGF‐beta1‐mediated tumor progression in pancreatic cancer
  publication-title: Mol Cancer Res
– volume: 92
  start-page: 2985
  issue: 12
  year: 2001
  end-page: 2992
  article-title: Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma
  publication-title: Cancer
– volume: 33
  start-page: 78
  issue: 3
  year: 2015
  end-page: 85
  article-title: High levels of cell‐free circulating nucleic acids in pancreatic cancer are associated with vascular encasement, metastasis and poor survival
  publication-title: Cancer Invest
– volume: 54
  start-page: 385
  issue: 3
  year: 2005
  end-page: 387
  article-title: Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re‐evaluating the data of the Finnish Cancer Registry
  publication-title: Gut
– volume: 230
  start-page: 776
  issue: 6
  year: 1999
  end-page: 782
  article-title: Adjuvant radiotherapy and 5‐fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group
  publication-title: Ann Surg
– volume: 7
  start-page: 497
  issue: 6
  year: 1998
  end-page: 504
  article-title: A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 15
  start-page: 145
  issue: 2
  year: 2015
  end-page: 150
  article-title: Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer
  publication-title: Pancreatology
– volume: 109
  start-page: 416
  issue: 2
  year: 2013
  end-page: 421
  article-title: Increased neutrophil‐lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer
  publication-title: Br J Cancer
– volume: 20
  start-page: 195
  issue: 3
  year: 2014
  end-page: 202
  article-title: Pancreatic cancer, inflammation, and microbiome
  publication-title: Cancer J
– volume: 13
  start-page: 5262
  issue: 18 Pt 1
  year: 2007
  end-page: 5270
  article-title: Transforming growth factor‐beta and the immune response: implications for anticancer therapy
  publication-title: Clin Cancer Res
– volume: 8
  start-page: 369
  issue: 5
  year: 2005
  end-page: 380
  article-title: TGF‐beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
  publication-title: Cancer Cell
– volume: 45
  start-page: 228
  issue: 2
  year: 2009
  end-page: 247
  article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
  publication-title: Eur J Cancer
– volume: 6
  start-page: 41228
  issue: 38
  year: 2015
  end-page: 41236
  article-title: Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
  publication-title: Oncotarget
– ident: e_1_2_9_30_1
  doi: 10.18632/oncotarget.5682
– ident: e_1_2_9_25_1
  doi: 10.1634/theoncologist.2016-0178
– ident: e_1_2_9_8_1
  doi: 10.1056/NEJMoa1304369
– ident: e_1_2_9_11_1
  doi: 10.18632/oncotarget.3069
– ident: e_1_2_9_34_1
  doi: 10.1158/1078-0432.CCR-1096-03
– ident: e_1_2_9_41_1
  doi: 10.1200/JCO.2005.05.3934
– ident: e_1_2_9_38_1
  doi: 10.1371/journal.pone.0085942
– ident: e_1_2_9_39_1
  doi: 10.4143/crt.2018.311
– ident: e_1_2_9_12_1
  doi: 10.1038/onc.2013.29
– ident: e_1_2_9_27_1
  doi: 10.1016/j.ejca.2008.10.026
– ident: e_1_2_9_2_1
  doi: 10.1136/gut.2004.047191
– ident: e_1_2_9_13_1
  doi: 10.1038/bjc.2013.332
– ident: e_1_2_9_6_1
  doi: 10.1016/S0140-6736(04)15841-8
– ident: e_1_2_9_28_1
  doi: 10.1016/j.bbrc.2017.05.034
– ident: e_1_2_9_3_1
  doi: 10.1002/bjs.4484
– ident: e_1_2_9_5_1
  doi: 10.1097/00000658-199912000-00006
– ident: e_1_2_9_9_1
  doi: 10.1186/1476-4598-12-66
– volume: 7
  start-page: 497
  issue: 6
  year: 1998
  ident: e_1_2_9_23_1
  article-title: A subset of metastatic human colon cancers expresses elevated levels of transforming growth factor beta1
  publication-title: Cancer Epidemiol Biomarkers Prev
  contributor:
    fullname: Picon A
– ident: e_1_2_9_31_1
  doi: 10.18632/oncotarget.8847
– ident: e_1_2_9_10_1
  doi: 10.1038/sj.bjc.6604745
– ident: e_1_2_9_17_1
  doi: 10.1038/cr.2008.316
– volume: 3
  start-page: 326
  issue: 4
  year: 2012
  ident: e_1_2_9_4_1
  article-title: Treatment of locally advanced unresectable pancreatic cancer: a 10‐year experience
  publication-title: J Gastrointest Oncol
  contributor:
    fullname: Malik NK
– ident: e_1_2_9_35_1
  doi: 10.1002/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5
– ident: e_1_2_9_37_1
  doi: 10.1002/(SICI)1097-0142(19990201)85:3<554::AID-CNCR6>3.0.CO;2-X
– ident: e_1_2_9_24_1
  doi: 10.1016/0016-5085(93)91084-U
– ident: e_1_2_9_14_1
  doi: 10.1016/j.pan.2014.12.004
– ident: e_1_2_9_32_1
  doi: 10.1007/s00432-016-2184-6
– ident: e_1_2_9_20_1
  doi: 10.1158/1078-0432.CCR-07-1157
– ident: e_1_2_9_19_1
  doi: 10.1038/nrc1208
– ident: e_1_2_9_33_1
  doi: 10.18632/oncotarget.10069
– ident: e_1_2_9_26_1
  doi: 10.3109/07357907.2014.1001894
– ident: e_1_2_9_36_1
  doi: 10.1016/j.cca.2006.02.027
– ident: e_1_2_9_15_1
  doi: 10.1097/PPO.0000000000000045
– volume: 52
  start-page: 6949
  issue: 24
  year: 1992
  ident: e_1_2_9_22_1
  article-title: Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer
  publication-title: Can Res
  contributor:
    fullname: Gorsch SM
– ident: e_1_2_9_29_1
  doi: 10.1023/A:1018814416903
– ident: e_1_2_9_40_1
  doi: 10.1093/neuonc/nox097
– ident: e_1_2_9_7_1
  doi: 10.1056/NEJMoa1011923
– ident: e_1_2_9_21_1
  doi: 10.1016/j.ccr.2005.10.012
– ident: e_1_2_9_16_1
  doi: 10.1159/000108959
– ident: e_1_2_9_18_1
  doi: 10.1158/1541-7786.MCR-12-0511
SSID ssj0000702671
Score 2.2859385
Snippet Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated...
Transforming growth factor-beta (TGF-β) is a multifunctional regulatory factor. Here we measured serum soluble TGF-β (sTGF-β) levels and evaluated its dynamics...
Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and...
ObjectivesTransforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and evaluated...
Pre‐treatment sTGF‐β levels serve as a prognostic indicator in unresectable pancreatic cancer patients treated with FOLFIRINOX chemotherapy. The dynamics of...
Abstract Objectives Transforming growth factor‐beta (TGF‐β) is a multifunctional regulatory factor. Here we measured serum soluble TGF‐β (sTGF‐β) levels and...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 43
SubjectTerms Antigens
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
biomarker
Biomarkers
Biomarkers, Tumor - blood
Blood
Blood platelets
Chemotherapy
Clinical Cancer Research
Diagnosis
Disease Progression
Female
Fluorouracil - therapeutic use
Growth factors
Humans
Irinotecan - therapeutic use
Kaplan-Meier Estimate
Laboratories
Leucovorin - therapeutic use
Lymphocytes
Male
Medical prognosis
Metastasis
Middle Aged
Neutrophils
Original Research
Oxaliplatin - therapeutic use
Palliative Care - methods
Pancreatic cancer
Pancreatic Neoplasms - blood
Pancreatic Neoplasms - drug therapy
Pancreatic Neoplasms - mortality
Pathogenesis
Patients
Prognosis
Progression-Free Survival
Prospective Studies
Survival
Transforming Growth Factor beta - blood
Transforming growth factor-b
transforming growth factor‐beta
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NTtwwELYqDlUvFfQHArSyqh56CcSxHcdHirpFlbYnkLhZ_ou6B7JoNyD11kfgGXmSzthZtCuouPRmOYliz3y2Z-zxN4R8hiWL2Sq40gIgStG4tnQKxpVgdSVDcLbq0FGc_mzOLsSPS3m5luoLY8IyPXAW3DGLWjseQy1hIo3Ka-G8b6tGd52FcZqv-TK55kylOVhhZiW2ohKq6mNvr8QR1KmNBSjx9D9lXD6OkVy3XdPiM9kmr0erkZ7k1u6QF7F_Q15Ox3Pxt-QWtE0x1KqfI-8yxZhBOu8oAstB8fz75P7PnYuDpbYPdDYsacip6Jd01tObxPnjB7xGRWF6yJakpx4hsaApGD0Ginu2FJR8Nd7a-v2OXEy-nZ-elWNGhdKDYaBK4XTbCiGDAD9GMuWF7qJijnELQm5tDEiRyFspnfMtj1xI60BmtuY2Vlbx92Srn_dxj1BY-nRspUOyF-G1t96CK2O5q-rgZWAF-bQSs7nOxBkmUyTXBnVhUBcF-YoKeHgBua5TBSDAjAgwzyGgIIcr9ZlxAC5NzTkemYIHXpDdrMmHv3DkoG-ELIja0PFGMzaf9LNfiXq70WBw4ZdfEhr-3TNzejIVWNj_H108IK9q9PPT1s8h2RoWN_EDGEOD-5hw_xc74QkJ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: AUTh Library subscriptions: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3LbtQwFLWglRAbxJuUFlmIBZvQxI_YWVVt1aFCmgqhVurO8it0Fk3KTIrUXT-h38iXcG_iGRjx2EVOojg-175PHxPyDlRWaYvgcgsCkYvK6dwpmFeiZIUMwdmiQUdxelIdn4lP5_I8BdwWqaxyuSYOC3XoPMbIdxnnmAMDl2rv6luOp0ZhdjUdoXGfbLJSYJp28-Do5POXVZQFBJpVqlxSChVs19tL8QHa1JoiGvj6_2Zk_lkr-bsNOyihyWPyKFmPdH-E-wm5F9un5ME05cefke-AOsWSq7ZD_mWKtYO0aygKmIPL04-TH7d3LvaW2jbQWb-gYTySfkFnLb0euH98j9upKCwTo0XpqUfRmNOhKD0GirFbCmBfpt1bN8_J2eTo9PA4Tycr5B4MBJULV2sthAwC_BlZKi_qJqrSldzWjmsbA1Ilci2lc17zyIW0DsbMMm5jYRV_QTbaro2vCAUVWEctHZK-CF976y24NJa7ggUvQ5mRt8thNlcjgYYZqZKZQSwMYpGRAwRg9QByXg8N3fyrSVPIlLGGzsXAJKjUqHwtnPe6qOqmsbBi64xsL-EzaSIuzC-xycjLEcnVVzhy0VdCZkStYbzWjfU77exioOCuajC88M33gzT8-8_M4f5U4MXW_3v3mjxk6MkPwZ1tstHPr-MOmDu9e5Nk-iez8AGX
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwEB6VIlW9IN4ECrIQBy4pSWzH8QGhUrFUSMupK_Vm-RVYiWZhN5Xov2fGSapd0d6sJJYdz2fPjD3-BuAdqqzSFsHlFgGRi9o1uVM4r0RZFTIEZ4uWHMX59_psIb5dyIs9mHJsjgO4udW1o3xSi_Wv479_rj_hhP84Eoh-8PZSHFe1UvfgfiW4IKDPRys_LciK0iyVE6_Qdo1DOODESF7TdaYtxZT4-28zOv-Pndy2aZNSmj2EB6M1yU4G8T-Cvdg9hoP5eF7-BHpEAaMQrG5FfMyMYgnZqmUEOIfF86-z3MXeMtsFtuw3LAwJ6jds2bGrxATke7pcxXDRGOxLzzwBZc1SiHoMjHZyGYr-crzLdf0UFrMv56dn-ZhnIfdoLqhcON00Qsgg0LuRpfJCt1GVruRWO97YGIg4kTdSOucbHrmQ1uHg2YrbWFjFn8F-t-riC2CoEHVspCMKGOG1t96ig2O5K6rgZSgzeDsNsvk90GmYgTi5MiQUQ0LJ4DMN_80HxICdHqzWP8w4oUwZNXYuhkqigo3Ka-G8b4pat63F9bvJ4GgSnplQZSrO6SAV_fIMng9yvGllwkEGakfCO93YfdMtfyZC7lqjGUY13ycs3P1n5vRkLqjw8s7mX8FhRS592uU5gv1-fRVfo93TuzcJ1f8A1l8AGA
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley-Blackwell Open Access Collection
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3LbtQwFLVKkRAbVJ4NFGQhFmxCEz9iW121FUOFNIhFK3Vn-RWYRTNoJkVixyfwjXwJ9zqZ0BEgsYtiW3F87vV92D4m5BWYrNpV0ZcOBKIUjdelV6BXomaVjNG7qsVAcf6hObsQ7y_l5Q452pyFGfghpoQbakaer1HBnV8f_iYNDe5KvGGNUrfIbXBrNIo0Ex-nBAvIMpRiwIWM6yXokdgwC1XscGq9ZY8ybf_ffM0_t0zedGWzLZrtkXujE0mPB9Tvk53UPSB35uMy-UPyFcCnuPOqWyINM8UthHTZUpQzD4_n72Y_v__wqXfUdZEu-jWNw830a7ro6HWmAAo9nqqiMFsMjmWgASVkRfPe9BQppnApYH41HuL69ohczN6en56V4wULZQA_QZXCG62FkFFAWCNrFYRpk6p9zZ3xXLsUkTGRaym9D5onLqTzMGaOcZcqp_hjststu7RPKFhCk7T0yP0iggkuOIhsHPcVi0HGuiAvN8Nsvww8GnZgTGYWsbCIRUFOEICpAlJf5xfL1Sc7apKtk4HOpcgkWNakghE-BF01pm0dTNy6IAcb-Oyoj2vLOMcVVAjIC_JkQHL6CkdK-kbIgqgtjLe6sV3SLT5nJu7GgP-FLV9nafj3n9nT47nAh6f_X_UZucswuM_5ngOy26-u03PwgHr_Ikv6LwB9Ajc
  priority: 102
  providerName: Wiley-Blackwell
Title The prognostic role of soluble TGF‐beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcam4.2677
https://www.ncbi.nlm.nih.gov/pubmed/31701645
https://www.proquest.com/docview/2333501133
https://pubmed.ncbi.nlm.nih.gov/PMC6943145
https://doaj.org/article/1e99b3ed25284e7c94bcc8069ffa1118
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fa9swED-aDsZexv7PXRfE2MNenNiWZNmPbWhaBilhtJA3o3_ZAo1TknSwt36EfcZ9kt3JdknY9rIXIWyDZP1Oujvp7ieAj6iyUp04E2sUiFjkpoiNwnkl0iyRzhmdzMlRnFzmF9fi80zODkB2uTAhaN-axaC-WQ7qxbcQW3m7tMMuTmw4nYzyEtWekMMe9BTnOy56WH4VXaqUdixCSTa0eikG-Iwu3OPEP55T8tKOGgps_X8zMf-MlNy1YIMKGj-Dp63tyE6aPj6HA1-_gMeT9nT8JXxHzBkFXNUrYl9mFDnIVnNG4mWwenU-_nX_0_itZrp2bLHdMNdcSL9hi5rdBeYfu6VkKoaLRGNPWmZJMNYshKR7x2jnliHUyzZ368cruB6fXY0u4vZehdiieaBiYcqiEEI6gd6MTJUV5dyr1KRcl4YX2jsiSuSFlMbYgnsupDY4fDrj2ida8ddwWK9q_xYYKsDSF9IQ5YuwpdVWo0OjuUkyZ6VLI_jQDXN129BnVA1RclYRLBXBEsEpAfDwATFehwer9deqxb1KfYmd8y6TqFC9sqUw1hZJXs7nGtfrIoLjDr6qnYabKuOcDk7RD4_gTYPkQyudJESg9jDe68b-G5THQMDdyl8En4I0_PvPqtHJRFDl6L8beQdPMnLxw67PMRxu13f-PdpBW9OHXiamWKqZ6sOj07PL6Zd-2FPA8nyWYjkRRT_Mjt-wkA9j
link.rule.ids 230,315,733,786,790,870,891,2115,2236,11589,12083,21416,24346,27955,27956,31752,33777,43343,43838,46085,46509,50847,50956,53825,53827,74100,74657
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKwEXxLMECliIA5fQJLYT-4TaqssC3RVCW6k3y6_AHpqU3RSJGz-B38gvYSbxLqx43CInURx_Y8_D428IeQ4qKzeZt6kBgUh5aWVqK5hXPC8y4b01WY2O4nRWTk752zNxFgNuq5hWuV4T-4Xatw5j5PsFY7gHBi7Vq4vPKVaNwt3VWELjKtlByk05IjuHx7P3HzZRFhDooqzyNaVQVuw7c85fQlu1pYh6vv6_GZl_5kr-bsP2Smh8i9yM1iM9GOC-Ta6E5g65No3743fJF0CdYspV0yL_MsXcQdrWFAXMwuX89fjHt-82dIaaxtNFt6J-KEm_oouGXvbcP67D41QUlonBonTUoWgsaZ-UHjzF2C0FsM_j6a2v98jp-Hh-NEljZYXUgYFQpdwqKTkXnoM_I_LKcVWHKrc5M8oyaYJHqkQmhbDWSRYYF8bCmJmCmZCZit0no6ZtwgNCQQWqIIVF0hfulDPOgEtjmM0K74TPE_JsPcz6YiDQ0ANVcqERC41YJOQQAdg8gJzXfUO7_KjjFNJ5UNC54AsBKjVUTnHrnMxKVdcGVmyZkL01fDpOxJX-JTYJ2R2Q3HyFIRd9yUVCqi2Mt7qxfadZfOopuEsFhhe--aKXhn__mT46mHK8ePj_3j0l1yfz6Yk-eTN794jcKNCr7wM9e2TULS_DYzB9OvskyvdPCdkEjQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELaglSouiDeBFizEgUvYJLbj5FS1pUt57KpCrdSb5VdgD03KborEjZ_Ab-wv6YzjXVjxuEVOojiez56Hx98Q8hJUVq4zZ1INgEh5aarUSJhXPC8y4ZzRWYOO4mRaHp3y92fiLOY_LWJa5XJNDAu16yzGyEcFY7gHBi7VqIlpEcdvxrsXX1OsIIU7rbGcxk2yKXkpwBHb3D-cHn9aRVwA3EUp8yW9UFaMrD7nr6FNrimlwN3_N4Pzz7zJ3-3ZoJDGd8jtaEnSvUH0d8kN394jW5O4V36ffAMEUEy_ajvkYqaYR0i7hiLYDFyevB1f_fhpfK-pbh2d9QvqhvL0Czpr6WXgAbI9Hq2isGQM1qWlFmEypyFB3TuKcVwKgj-PJ7m-PyCn48OTg6M0VllILRgLMuWmrirOhePg24hcWl43XuYmZ7o2rNLeIW0iq4QwxlbMMy60gTHTBdM-05I9JBtt1_rHhII6rH0lDBLAcFtbbTW4N5qZrHBWuDwhL5bDrC4GMg010CYXCmWhUBYJ2UcBrB5A_uvQ0M0_qzidVO5r6Jx3hQD16qWtubG2ysq6aTSs3lVCtpfiU3FSLtQvCCXk0SDJ1VcY8tKXXCRErsl4rRvrd9rZl0DHXdZghOGbrwIa_v1n6mBvwvHiyf9795xsAbTVx3fTD0_JrQId_BDz2SYb_fzS74AV1JtnEd7XHbgIwQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prognostic+role+of+soluble+TGF-beta+and+its+dynamics+in+unresectable+pancreatic+cancer+treated+with+chemotherapy&rft.jtitle=Cancer+medicine+%28Malden%2C+MA%29&rft.au=Park%2C+Hyunkyung&rft.au=Bang%2C+Ju-Hee&rft.au=Nam%2C+Ah-Rong&rft.au=Park%2C+Ji+Eun&rft.date=2020-01-01&rft.eissn=2045-7634&rft.volume=9&rft.issue=1&rft.spage=43&rft_id=info:doi/10.1002%2Fcam4.2677&rft_id=info%3Apmid%2F31701645&rft.externalDocID=31701645
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-7634&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-7634&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-7634&client=summon